Previous 10 | Next 10 |
WAYNE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Foo...
WAYNE, Pa., April 24, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 1...
The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this Read more ...
Private equity shops Apollo Global Management and CVC Capital Partners are apparently bidding for Perrigo's ( PRGO +2.6% ) generic pharmaceuticals unit according to informed sources who add that the business could fetch more than $2.5B. More news on: Perrigo Company plc, Akorn, In...
The year 2019 is an exciting time for Rigel Pharmaceuticals ( RIGL ) in many ways and not so much in others. On the one hand, the company will generate its first full year of sales data from Tavalisse (fostamatinib) which it began marketing for chronic immune thrombocytopenia ((ITP)) in late...
Leerink's Geoffrey Porges likes the upside of arthritis med filgotinib for Gilead Sciences (NASDAQ: GILD ), projecting a $5 - 6/share potential bump in value. He says the JAK1 inhibitor has an 80% (unclear how he arrived at this specific figure) chance of reaching $3.7B in peak sales (how fa...
WAYNE, Pa., March 27, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that management will attend the following conference: Management will host inve...
Aclaris Therapeutics (ACRS) Q4 2018 Earnings Conference Call March 18, 2019 08:00 ET Company Participants Kamil Ali-Jackson - Co-Founder and Chief Legal Officer Neal Walker - Co-Founder Chief Executive Officer, President and Director Stuart Shanler - Co-Founder and Chief Scientif...
Gainers: Dermira (NASDAQ: DERM ) +85% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +48% . Atossa Genetics (NASDAQ: ATOS ) +35% . American Midstream Partners (NYSE: AMID ) +28% . Aclaris Therapeutics (NASDAQ: ACRS ) +21% . Innovate Biopharmaceuticals (NASDAQ: INNT ) +20% . Profess...
Aclaris Therapeutics ( ACRS +22.4% ) is up on almost 30% higher volume following its Q4 report and 2019 outlook. Highlights: More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...